/GRTS

GRTS Stock - Gritstone bio, Inc.

Q: What is the analyst price target for GRTS?

Analyst price target information is not currently available for GRTS.

Q: What is GRTS's market cap?

Market capitalization information is not currently available for GRTS.

Healthcare|Biotechnology|NASDAQ

$0.03-31.78%

$0.01 (-31.78%) • Oct 21

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+14403.1%upside

Target: $4.67

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GRTS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.50

52W High$3.17

52W Low$0.03

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$1.33M	$9.27M	$46.72M	$4.04M	$4.37M
Gross Profit	$-6,260,000	$-6,422,000	$32.32M	$-84,606,000	$-78,531,000
Gross Margin	-470.3%	-69.3%	69.2%	-2095.8%	-1799.1%
Operating Income	$-154,634,000	$-120,428,000	$-75,209,000	$-106,017,000	$-97,940,000
Net Income	$-138,490,000	$-113,127,000	$-74,955,000	$-104,611,000	$-90,926,000
Net Margin	-10405.0%	-1220.5%	-160.4%	-2591.3%	-2083.1%
EPS	$-1.20	$-1.24	$-0.95	$-2.77	$-2.71

Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

75%

Hold / Neutral

Sell / Underperform

25%

Analyst Consensus🟢 Bullish

3 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 15428.0% Upside

Now

Low

Average

High

Based on 4 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 1st 2024	JMP Securities	Downgrade	Market Perform	-
February 28th 2024	JMP Securities	Initiation	Mkt Outperform	$4
March 31st 2023	Evercore ISI	Initiation	Outperform	-
March 28th 2023	B. Riley Securities	Initiation	Buy	$8
October 31st 2022	Piper Sandler	Initiation	Overweight	$6
August 22nd 2022	Goldman	Downgrade	Sell	$2

Earnings History & Surprises

GRTS

Beat Rate

71%

Last 17 quarters

Avg Surprise

+13.0%

EPS vs Estimate

Beats / Misses

12/4

1 met exactly

Latest EPS

$-0.33

Q4 2024

EPS Surprise History

Q1 23

+3.2%

$-0.30vs$-0.31

Q2 23

+6.3%

$-0.30vs$-0.32

Q3 23

+8.8%

$-0.31vs$-0.34

Q4 23

+5.7%

$-0.33vs$-0.35

Q1 24

+27.8%

$-0.26vs$-0.36

Q2 24

-13.3%

$-0.34vs$-0.30

Q3 24

+38.5%

$-0.16vs$-0.26

Q4 24

-73.7%

$-0.33vs$-0.19

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 11, 2025	—	—	—	—
Q2 2025	May 7, 2025	—	—	—	—
Q1 2025	Mar 3, 2025	—	—	—	—
Q4 2024	Nov 13, 2024	$-0.19	$-0.33	-73.7%	✗ MISS
Q3 2024	Aug 13, 2024	$-0.26	$-0.16	+38.5%	✓ BEAT
Q2 2024	May 9, 2024	$-0.30	$-0.34	-13.3%	✗ MISS
Q1 2024	Mar 5, 2024	$-0.36	$-0.26	+27.8%	✓ BEAT
Q4 2023	Nov 8, 2023	$-0.35	$-0.33	+5.7%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.34	$-0.31	+8.8%	✓ BEAT
Q2 2023	May 11, 2023	$-0.32	$-0.30	+6.3%	✓ BEAT
Q1 2023	Mar 9, 2023	$-0.31	$-0.30	+3.2%	✓ BEAT
Q4 2022	Nov 3, 2022	$-0.39	$-0.35	+10.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.40	$-0.34	+15.0%	✓ BEAT
Q2 2022	May 5, 2022	$-0.33	$-0.34	-3.0%	✗ MISS
Q1 2022	Mar 10, 2022	$-0.43	$-0.36	+16.3%	✓ BEAT
Q4 2021	Nov 3, 2021	$-0.44	$-0.36	+18.2%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.53	$-0.33	+37.7%	✓ BEAT
Q2 2021	May 6, 2021	$-0.39	$0.10	+125.6%	✓ BEAT
Q1 2021	Mar 11, 2021	$-0.69	$-0.69	0.0%	= MET
Q4 2020	Nov 5, 2020	$-0.68	$-0.69	-1.5%	✗ MISS